LMMY Exousia Bio, Inc.
Services-Educational Services · OTC · SEC CIK 1939937 · Fiscal year ends 05/31
Financial factors as of 2026-02-28 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-148.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-0.7%
ROA-0.7%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets1.2%
Debt / equity0.00x
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.36x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 | 2025Q12024-08-31 | 2024Q4*2024-05-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3,750 | $3,750 |
| Cost of revenue | $62,108 | $62,108 | $0 | $7,251 | $0 | $0 | $0 | — |
| Gross profit | -$62,108 | -$62,108 | $0 | -$7,251 | $0 | $0 | $3,750 | -$5,917 |
| SG&A expense | $0 | $0 | — | -$7,214 | $6,981 | $6,981 | $8,091 | -$228 |
| Operating income | -$237,005 | -$237,005 | -$31,814 | — | $6,981 | $6,981 | -$4,342 | — |
| Pretax income | -$19,083 | -$19,083 | -$31,814 | -$3,500 | $80,129 | $80,129 | -$3,911 | -$5,253 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19,083 | -$19,083 | -$31,814 | -$3,500 | $80,129 | $80,129 | -$3,911 | -$5,253 |
| EBITDA | — | -$236,437 | -$31,814 | — | $6,981 | $8,239 | -$666 | — |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.01 | 0.01 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.01 | 0.01 | 0.00 | — |
| Weighted avg. shares (diluted) | 16.76M | 16.76M | 7.78M | — | 7.78M | 7.78M | 7.78M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $1,028 | $1,028 | $1,028 | $1,028 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $15,250 | $15,250 | $11,500 |
| Current assets | $0 | $0 | $0 | $0 | $0 | $17,717 | $17,145 | $12,964 |
| PP&E, net | $670 | $670 | $0 | $0 | $0 | $2,435 | $3,693 | $4,952 |
| Intangibles | $0 | $0 | $0 | $0 | $0 | $4,703 | $7,120 | $9,537 |
| Total assets | $22.05M | $22.05M | $0 | $0 | $0 | $24,854 | $27,958 | $27,453 |
| Current liabilities | $261,023 | $261,023 | $35,314 | $0 | $0 | $0 | $17,169 | $14,169 |
| Total liabilities | $261,023 | $261,023 | $35,314 | $0 | $0 | $0 | $86,764 | $82,348 |
| Shareholders' equity | $21.79M | $21.79M | -$35,314 | $0 | $24,854 | $24,854 | -$58,805 | -$54,895 |
| Shares outstanding | 70.00M | 70.00M | 7.78M | 7.78M | 7.78M | 7.78M | 7.78M | 7.78M |
| Cash flow statement | ||||||||
| Operating cash flow | $0 | $173,126 | $3,500 | -$3,500 | -$87,566 | $87,954 | -$3,676 | -$1,414 |
| Capital expenditure | $0 | — | — | — | $0 | — | — | — |
| Free cash flow | $0 | — | — | — | -$87,566 | — | — | — |
| Investing cash flow | $0 | -$22.05M | $0 | $0 | $0 | $0 | $3,676 | $0 |
| Financing cash flow | $0 | $21.88M | -$3,500 | $3,500 | $86,538 | -$87,954 | $0 | $1,416 |
| Depreciation & amortization | $0 | $568 | $0 | $3,775 | $0 | $1,258 | $3,676 | $1,258 |
Free plan shows the latest 8 periods; Pro shows all 16 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.